Infectious Disease
RSSArticles
-
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
-
ECG Review
-
The Many Emotions of the Heart
-
BNP-Guided Heart Failure Prevention
-
Internal Medicine Alert - Full November 15, 2013 Issue in PDF
-
Fidaxomicin More Effective than Vancomycin for Clostridium difficile Infection in Cancer Patients?
-
Clarification
-
Pharmacology Update: Acyclovir Buccal Tablets (Sitavig)
The FDA has approved a buccal formulation of Acyclovir for the treatment of recurrent cold scores. The product uses a mucoadhesive technology that delivers the drug in high concentration to the site of the cold sore. Acyclovir buccal tablets are manufactured by Farmea in France and marketed as Sitavig by BioAlliance Pharma. -
Hemorrhagic Stoke with Dual Antiplatelet Therapy
The authors concluded that in CAD patients, a history of CVE increased the risk of subsequent cardiovascular events, including hemorrhagic stroke. -
Large Systematic Review of Vitamin and Antioxidant Supplements Finds No Impact on Risk of CVD
A systematic review and meta-analysis of 50 randomized controlled trials did not find that vitamin and antioxidant supplements reduce the risk of cardiovascular disease. Numerous subgroup analyses similarly found no benefit from daily supplementation, but also no adverse effects.